AIM Immunotech Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held on November 3, 2022. AIM Immunotech Inc. is a Delaware corporation with its principal executive offices in Ocala, Florida. The company's common stock trades on the NYSE American under the symbol "AIM".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
At the meeting, 48,049,300 shares were entitled to vote, with a quorum of 40.0% present. Key voting outcomes included:
- Election of Directors: All three nominees (Thomas K. Equels, William M. Mitchell, and Stewart L. Appelrouth) were elected to serve until the 2023 Annual Meeting.
- Auditor Ratification: Stockholders approved the selection of BDO USA, LLP as independent auditors for the fiscal year ending December 31, 2022.
- Executive Compensation: The non-binding vote on executive compensation was rejected by stockholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the significant rejection of the executive compensation proposal (10,213,253 votes against vs. 2,036,994 for).
- Confirm the high number of broker non-votes (9,831,146) which impacted the director election results.
- Note that Thomas K. Equels received the highest "For" vote count among directors, while William M. Mitchell and Stewart L. Appelrouth received significantly fewer "For" votes.
- Review the company's subsequent response to the failed executive compensation vote in future filings.